BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 25232099)

  • 1. Mechanism of allosteric inhibition of HIV-1 reverse transcriptase revealed by single-molecule and ensemble fluorescence.
    Schauer GD; Huber KD; Leuba SH; Sluis-Cremer N
    Nucleic Acids Res; 2014 Oct; 42(18):11687-96. PubMed ID: 25232099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allosteric suppression of HIV-1 reverse transcriptase structural dynamics upon inhibitor binding.
    Seckler JM; Barkley MD; Wintrode PL
    Biophys J; 2011 Jan; 100(1):144-53. PubMed ID: 21190666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efavirenz binding to HIV-1 reverse transcriptase monomers and dimers.
    Braz VA; Holladay LA; Barkley MD
    Biochemistry; 2010 Jan; 49(3):601-10. PubMed ID: 20039714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-nucleoside Reverse Transcriptase Inhibitors Inhibit Reverse Transcriptase through a Mutually Exclusive Interaction with Divalent Cation-dNTP Complexes.
    DeStefano JJ
    Biochemistry; 2019 Apr; 58(16):2176-2187. PubMed ID: 30900874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical mechanism of HIV-1 resistance to rilpivirine.
    Singh K; Marchand B; Rai DK; Sharma B; Michailidis E; Ryan EM; Matzek KB; Leslie MD; Hagedorn AN; Li Z; Norden PR; Hachiya A; Parniak MA; Xu HT; Wainberg MA; Sarafianos SG
    J Biol Chem; 2012 Nov; 287(45):38110-23. PubMed ID: 22955279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p66/p51 and p51/p51 recombinant forms of reverse transcriptase from human immunodeficiency virus type 1--interactions with primer tRNA(Lys3), initiation of cDNA synthesis, and effect of inhibitors.
    Dufour E; El Dirani-Diab R; Boulmé F; Fournier M; Nevinsky G; Tarrago-Litvak L; Litvak S; Andreola ML
    Eur J Biochem; 1998 Jan; 251(1-2):487-95. PubMed ID: 9492322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine.
    Schuckmann MM; Marchand B; Hachiya A; Kodama EN; Kirby KA; Singh K; Sarafianos SG
    J Biol Chem; 2010 Dec; 285(49):38700-9. PubMed ID: 20876531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonnucleoside inhibitor binding affects the interactions of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase with DNA.
    Peletskaya EN; Kogon AA; Tuske S; Arnold E; Hughes SH
    J Virol; 2004 Apr; 78(7):3387-97. PubMed ID: 15016861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes.
    Maga G; Ubiali D; Salvetti R; Pregnolato M; Spadari S
    Antimicrob Agents Chemother; 2000 May; 44(5):1186-94. PubMed ID: 10770750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efavirenz binding site in HIV-1 reverse transcriptase monomers.
    Braz VA; Barkley MD; Jockusch RA; Wintrode PL
    Biochemistry; 2010 Dec; 49(49):10565-73. PubMed ID: 21090588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
    Hu Z; Kuritzkes DR
    J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thumbs down for HIV: domain level rearrangements do occur in the NNRTI-bound HIV-1 reverse transcriptase.
    Wright DW; Sadiq SK; De Fabritiis G; Coveney PV
    J Am Chem Soc; 2012 Aug; 134(31):12885-8. PubMed ID: 22827470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The amino acid Asn136 in HIV-1 reverse transcriptase (RT) maintains efficient association of both RT subunits and enables the rational design of novel RT inhibitors.
    Balzarini J; Auwerx J; Rodríguez-Barrios F; Chedad A; Farkas V; Ceccherini-Silberstein F; García-Aparicio C; Velázquez S; De Clercq E; Perno CF; Camarasa MJ; Gago F
    Mol Pharmacol; 2005 Jul; 68(1):49-60. PubMed ID: 15833734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors.
    Xu HT; Colby-Germinario SP; Huang W; Oliveira M; Han Y; Quan Y; Petropoulos CJ; Wainberg MA
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5649-57. PubMed ID: 24002090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of HIV reverse transcriptase inhibition by zinc: formation of a highly stable enzyme-(primer-template) complex with profoundly diminished catalytic activity.
    Fenstermacher KJ; DeStefano JJ
    J Biol Chem; 2011 Nov; 286(47):40433-42. PubMed ID: 21953456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs.
    Auwerx J; Van Nieuwenhove J; Rodríguez-Barrios F; de Castro S; Velázquez S; Ceccherini-Silberstein F; De Clercq E; Camarasa MJ; Perno CF; Gago F; Balzarini J
    FEBS Lett; 2005 Apr; 579(11):2294-300. PubMed ID: 15848161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases: role of the subunits in resistance/sensitivity to non-nucleoside reverse transcriptase inhibitors.
    Auwerx J; North TW; Preston BD; Klarmann GJ; De Clercq E; Balzarini J
    Mol Pharmacol; 2002 Feb; 61(2):400-6. PubMed ID: 11809865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elucidating the inhibition mechanism of HIV-1 non-nucleoside reverse transcriptase inhibitors through multicopy molecular dynamics simulations.
    Ivetac A; McCammon JA
    J Mol Biol; 2009 May; 388(3):644-58. PubMed ID: 19324058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms.
    Hsiou Y; Ding J; Das K; Clark AD; Hughes SH; Arnold E
    Structure; 1996 Jul; 4(7):853-60. PubMed ID: 8805568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonnucleoside Reverse Transcriptase Inhibitor Hypersusceptibility and Resistance by Mutation of Residue 181 in HIV-1 Reverse Transcriptase.
    Barnard JP; Huber KD; Sluis-Cremer N
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31160281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.